{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:47:50Z","timestamp":1767962870495,"version":"3.49.0"},"reference-count":72,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.antiviral.2014.01.010","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T15:04:41Z","timestamp":1390489481000},"page":"60-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["The competitive binding between inhibitors and substrates of HCV NS3\/4A protease: A general mechanism of drug resistance"],"prefix":"10.1016","volume":"103","author":[{"given":"Yan","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peichen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingjun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.01.010_b0005","unstructured":"Discovery Studio 2.5 Guide, Accelrys Inc., San Diego, 2009, http:\/\/www.accelrys.com."},{"key":"10.1016\/j.antiviral.2014.01.010_b0010","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S1590-8658(07)80018-1","article-title":"Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment","volume":"39","author":"Almasio","year":"2007","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.antiviral.2014.01.010_b0015","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.010_b0020","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1021\/j100142a004","article-title":"A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model","volume":"97","author":"Bayly","year":"1993","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.antiviral.2014.01.010_b0025","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1073\/pnas.80.21.6571","article-title":"Harmonic dynamics of proteins: normal modes and fluctuations in bovine pancreatic trypsin inhibitor","volume":"80","author":"Brooks","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.01.010_b0030","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.antiviral.2014.01.010_b0035","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/hep.22122","article-title":"Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-na\u00efve chronically infected patient","volume":"47","author":"Colson","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.01.010_b0040","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N log (N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.antiviral.2014.01.010_b0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/jir315","article-title":"Antiviral activity of danoprevir (ITMN-191\/RG7227) in combination with pegylated interferon \u03b1-2a and ribavirin in patients with hepatitis C","volume":"204","author":"Forestier","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.01.010_b0050","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.010_b0055","series-title":"Gaussian 09","author":"Frisch","year":"2009"},{"key":"10.1016\/j.antiviral.2014.01.010_b0060","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0022-2836(03)00610-7","article-title":"Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RaIGDS complexes","volume":"330","author":"Gohlke","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0070","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/prot.21123","article-title":"Comparison of multiple Amber force fields and development of improved protein backbone parameters","volume":"65","author":"Hornak","year":"2006","journal-title":"Proteins: Struct. Funct. Bioinf."},{"key":"10.1016\/j.antiviral.2014.01.010_b0075","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/prot.22192","article-title":"Predicting drug resistance of the HIV-1 protease using molecular interaction energy components","volume":"74","author":"Hou","year":"2009","journal-title":"Proteins: Struct. Funct. Bioinf."},{"key":"10.1016\/j.antiviral.2014.01.010_b0080","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1021\/pr3000688","article-title":"Characterization of domain-peptide interaction interface. Prediction of SH3 domain-mediated protein-protein interaction network in yeast by generic structure-based models","volume":"11","author":"Hou","year":"2012","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.antiviral.2014.01.010_b0085","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/prot.21808","article-title":"Evaluating the potency of HIV-1 protease drugs to combat resistance","volume":"71","author":"Hou","year":"2008","journal-title":"Proteins: Struct. Funct. Bioinf."},{"key":"10.1016\/j.antiviral.2014.01.010_b0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods: I. The accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2014.01.010_b0095","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcc.21666","article-title":"Assessing the performance of the molecular mechanics\/Poisson Boltzmann surface area and molecular mechanics\/generalized born surface area methods. II. The accuracy of ranking poses generated from docking","volume":"32","author":"Hou","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.antiviral.2014.01.010_b0100","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1074\/mcp.M800450-MCP200","article-title":"Characterization of domain-peptide interaction interface. A generic structure-based model to decipher the binding specificity of SH3 domains","volume":"8","author":"Hou","year":"2009","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.antiviral.2014.01.010_b0105","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/jm0609162","article-title":"Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance","volume":"50","author":"Hou","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2014.01.010_b0110","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jmb.2007.12.054","article-title":"Characterization of domain-peptide interaction interface. A case study on the amphiphysin-1 SH3 domain","volume":"376","author":"Hou","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0115","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/S0168-8278(10)60652-6","article-title":"650 antiviral activity, combination and resistance of ACH-1625, a potent, clinical stage HCV NS3 protease inhibitor","volume":"52","author":"Huang","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0120","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1021\/jm010338j","article-title":"Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design","volume":"45","author":"Huo","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2014.01.010_b0125","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.3748\/wjg.14.6627","article-title":"Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2\/3?","volume":"14","author":"Jamall","year":"2008","journal-title":"World J. gastroenterol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0130","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.antiviral.2014.01.010_b0135","first-page":"1","article-title":"Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach","author":"Karthick","year":"2012","journal-title":"J. Phys. Chem. B."},{"key":"10.1016\/j.antiviral.2014.01.010_b0140","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.antiviral.2014.01.010_b0145","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1074\/jbc.M110.211417","article-title":"Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3\u2013NS4A protease inhibitor BI 201335","volume":"286","author":"Lemke","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2014.01.010_b0150","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.010_b0155","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1021\/ci300375k","article-title":"Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A\/H1N1 influenza neuraminidase","volume":"52","author":"Li","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2014.01.010_b0160","article-title":"Study of Tamiflu Sensitivity to Variants of A\/H5N1 Virus Using Different Force Fields","author":"Li","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2014.01.010_b0165","doi-asserted-by":"crossref","DOI":"10.2174\/187152606776056706","article-title":"Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis \u0441 virus NS3\u2217 4A serine protease","volume":"6","author":"Lin","year":"2006","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.antiviral.2014.01.010_b0170","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1021\/mp100041b","article-title":"In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase","volume":"7","author":"Liu","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.antiviral.2014.01.010_b0175","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","article-title":"SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells","volume":"50","author":"Malcolm","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.010_b0180","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1006\/viro.1994.1075","article-title":"Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3","volume":"198","author":"Manabe","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.01.010_b0185","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.010_b0190","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.010_b0195","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA. py: An efficient program for end-state free energy calculations","author":"Miller","year":"2012","journal-title":"J. Chem. Theory. Comput."},{"key":"10.1016\/j.antiviral.2014.01.010_b0200","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/prot.20033","article-title":"Exploring protein native states and large-scale conformational changes with a modified generalized born model","volume":"55","author":"Onufriev","year":"2004","journal-title":"Proteins: Struct. Funct. Bioinf."},{"key":"10.1016\/j.antiviral.2014.01.010_b0210","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jmb.2011.03.053","article-title":"Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope","volume":"410","author":"Ozen","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0215","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jmb.2011.03.053","article-title":"Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope","volume":"410","author":"\u00d6zen","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0220","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.bbagen.2012.06.001","article-title":"Understanding the drug resistance mechanism of hepatitis C virus NS3\/4A to ITMN-191 due to R155K, A156V, D168A\/E mutations: a computational study","volume":"1820","author":"Pan","year":"2012","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"10.1016\/j.antiviral.2014.01.010_b0225","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.010_b0230","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bmcl.2004.01.022","article-title":"Inhibitors of hepatitis C virus NS3 4A protease 2. Warhead SAR and optimization","volume":"14","author":"Perni","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2014.01.010_b0235","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","article-title":"Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes","volume":"10","author":"Prabu-Jeyabalan","year":"2002","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2014.01.010_b0240","doi-asserted-by":"crossref","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.01.010_b0245","doi-asserted-by":"crossref","first-page":"20986","DOI":"10.1073\/pnas.1006370107","article-title":"Drug resistance against HCV NS3\/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding","volume":"107","author":"Romano","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.01.010_b0250","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1128\/JVI.00377-11","article-title":"Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3\/4A protease","volume":"85","author":"Romano","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.010_b0255","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2014.01.010_b0260","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"10.1016\/j.antiviral.2014.01.010_b0265","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.01.010_b0270","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.01.010_b0275","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.1021\/bi980313v","article-title":"Product inhibition of the hepatitis C virus NS3 protease","volume":"37","author":"Steink\u00fchler","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2014.01.010_b0280","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bbrc.2012.05.120","article-title":"A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK","volume":"423","author":"Sun","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2014.01.010_b0285","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.00135-10","article-title":"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease","volume":"54","author":"Tong","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.010_b0290","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.antiviral.2014.01.010_b0295","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/157340906778226454","article-title":"Recent advances in free energy calculations with a combination of molecular mechanics and continuum models","volume":"2","author":"Wang","year":"2006","journal-title":"Curr. Comput.-Aided Drug Des."},{"key":"10.1016\/j.antiviral.2014.01.010_b0300","doi-asserted-by":"crossref","first-page":"14937","DOI":"10.1073\/pnas.251265598","article-title":"Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance","volume":"98","author":"Wang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.01.010_b0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A","article-title":"Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO)","volume":"20","author":"Weiser","year":"1999","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.antiviral.2014.01.010_b0310","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1136\/gutjnl-2012-302144","article-title":"New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives","volume":"61","author":"Welsch","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2014.01.010_b0315","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.05184-11","article-title":"Ketoamide resistance and hepatitis C virus fitness in Val55 variants of the NS3 serine protease","volume":"56","author":"Welsch","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.010_b0320","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CMR.00010-06","article-title":"Viral determinants of resistance to treatment in patients with hepatitis C","volume":"20","author":"Wohnsland","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2014.01.010_b0325","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1021\/jp404160y","article-title":"Assessing the performance of MM\/PBSA and MM\/GBSA methods. 3. The impact of force fields and ligand charge models","volume":"117","author":"Xu","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.antiviral.2014.01.010_b0330","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.antiviral.2011.11.007","article-title":"Molecular modeling study on the resistance mechanism of HCV NS3\/4A serine protease mutants R155K, A156V and D168A to TMC435","volume":"93","author":"Xue","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2014.01.010_b0335","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1039\/c2mb25157d","article-title":"Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3\/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis","volume":"8","author":"Xue","year":"2012","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.antiviral.2014.01.010_b0340","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1039\/c2mb25114k","article-title":"Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study","volume":"8","author":"Xue","year":"2012","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.antiviral.2014.01.010_b0345","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1039\/c2mb25042j","article-title":"Understanding the molecular basis of MK2\u2013p38\u03b1 signaling complex assembly: insights into protein\u2013protein interaction by molecular dynamics and free energy studies","volume":"8","author":"Yang","year":"2012","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.antiviral.2014.01.010_b0350","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/ci100427j","article-title":"Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors","volume":"51","author":"Yang","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2014.01.010_b0355","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1021\/ci200159g","article-title":"Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38\u03b1 MAP kinase","volume":"51","author":"Yang","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2014.01.010_b0360","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1073\/pnas.0907304107","article-title":"Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance","volume":"107","author":"Zhang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T19:51:41Z","timestamp":1565121101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":72,"alternative-id":["S0166354214000229"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.010","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The competitive binding between inhibitors and substrates of HCV NS3\/4A protease: A general mechanism of drug resistance","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}